ClinicalTrials.gg
RecruitingNCT06385925Updated Nov 16, 2026

A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

A Phase 1/2 interventional study of TSN1611 and TSN1611 in Malignant Neoplasm, sponsored by Tyligand Pharmaceuticals (Suzhou) Limited. Recruiting at 24 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Tyligand Pharmaceuticals (Suzhou) Limited · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 6 months later.
Updated Nov 16, 2026Primary completion movedStudy completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
570
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The study is a first-in-human (FIH), open-label, multi-center phase 1/2 study of TSN1611 in subjects with KRAS G12D mutant advanced solid tumors. This study will consist of a phase 1a dose escalation/confirmation part, phase 1b dose randomization part and phase 2 dose expansion parts of TSN1611 as monotherapy or in combination with other anti-cancer therapies. This study will evaluate the efficacy of TSN1611 at RP2D(s) through ORR using RECIST version 1.1, and determine and confirm the MTD/RP2D for TSN1611 in combination with cetuximab, in combination with cetuximab and mFOLFOX6, in combination with cetuximab and FOLFIRI, in combination with gemcitabine and albumin-bound paclitaxel in subjects with selected solid tumors.

Read the detailed description

Phase 1 Part of TSN1611 Monotherapy:

The phase 1 part will evaluate the prespecified dose levels of TSN1611. Dose escalation will continue until up to the highest planned dose or the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) is determined. Dose optimization could be performed as indicated by the emerging data.

Phase 2 Part of TSN1611 Monotherapy:

phase 2 part of TSN1611 monotherapy will evaluate the efficacy and safety of TSN1611 as monotherapy at the RP2D until disease progression or unacceptable toxicity in separate groups of patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer, or other solid tumors, harboring KRAS G12D mutations.

Phase 1b/2 Part of TSN1611 Combination Therapy:

This part will consist of the investigations of 4 combined therapies (Cohort A, B ,C and D). In each cohort, there will be a Phase 1b Safety Lead-in Stage to determine the dose of TSN1611 for the combination therapy (this part will be conducted in selected sites), followed by the Phase 2 Expansion Stage to enroll more subjects to determine the efficacy in different cohorts.

02

Conditions studied

  • Malignant Neoplasm

Keywords

  • solid tumor
  • KRAS G12D mutation
  • pancreatic cancer
  • colorectal cancer
  • non-small cell lung cancer
  • malignant neoplasm
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 570 is above the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

This is the only study on the registry with Tyligand Pharmaceuticals (Suzhou) Limited as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 16, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Subjects must meet all the following inclusion criteria to be eligible for participation in this study:

  • The subject fully understands the requirements of the study and voluntarily signs the ICF.
  • At least 18 years of age at the time of .≤ 75 years of age for Cohort B and C.
  • of 3 months or more.
  • (ECOG) performance status 0 or 1.
  • Phase 1 part (1a/1b) of Monotherapy:

Subjects with or cytologically confirmed locally advanced or solid tumor harboring KRAS G12D mutation; subjects must be or intolerable to standard treatment, or have no standard treatment available, or the subject is ineligible or declines standard treatment.

Phase 2 part of TSN1611 Monotherapy:

Subjects with histologically or cytologically confirmed locally advanced or metastatic PDAC、CRC and NSCLC harboring KRAS G12D mutation; According to the requirements of different combined cohorts, the number of previous treatments is taken into account.

Phase 1b/2 Part of TSN1611 in Combination Therapies:

Subjects with histologically or cytologically confirmed locally advanced or metastatic PDAC、CRC and NSCLC harboring KRAS G12D mutation; According to the requirements of different combined cohorts, the number of previous treatments is taken into account.

  • Patients with adequate cardiac, liver, renal function, etc.

Exclusion Criteria

Subjects will be excluded if they meet any of the following criteria:

  • or Active central nervous system (CNS) metastases.
  • Prior systemic anti-cancer treatment within 21 days or 5 half-lives (whichever is shorter will be used as the criteria) prior to the first dose of study drug.
  • Radical radiation within 4 weeks prior to the first dose of study drug; palliative radiotherapy within 1 week prior to the first dose of study drug.
  • Any unresolved Grade 2 or higher toxicity from previous anticancer therapy except alopecia.
  • Has participated in a study of agent and received the investigational agent within 21 days or 5 half-lives, if known (whichever is shorter) prior to the first dose of study drug.
  • History of interstitial lung disease (ILD), drug induced IDL, or current active pneumonitis, radiation pneumonitis requiring therapeutic intervention, or uncontrolled other lung disease.
  • Any of the following in the past 6 months: myocardial infarction, unstable angina, symptomatic congestive heart failure, stroke or , pulmonary embolism.
  • Prior treatment with KRAS G12D targeted therapy.
  • Has a history or current evidence of any severe condition, concurrent therapy, or laboratory abnormality that might confound the interpretation of the study results, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the investigator.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
570 participants (estimated)

Study arms

  • Experimental
    Phase 1a: Dose-finding/evaluation of TSN1611 monotherapy

    The phase 1 part will evaluate the prespecified sequential dose levels of TSN1611 in subjects with KRAS G12D mutant advanced solid tumors to determine the recommended dose of TSN1611 for further investigation.

    Drug: TSN1611

  • Experimental
    Phase 2: Dose expansion of TSN1611 monotherapy

    Phase 2 part will evaluate the efficacy and safety of TSN1611 as monotherapy at the recommended dose level in separate groups of patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer, or other solid tumors, harboring KRAS G12D mutations.

    Drug: TSN1611

  • Experimental
    Dose of Phase 1b/2 part of TSN1611 combination therapy-Cohort A

    Cohort A: TSN1611 combined with cetuximab treating subjects with advanced solid tumors harboring KRAS G12D mutation:

    Drug: TSN1611

  • Experimental
    Dose of Phase 1b/2 part of TSN1611 combination therapy-Cohort B

    Cohort B: TSN1611 combined with GnP regimen (i.e., gemcitabine and nab-paclitaxel) treating subjects with advanced PDAC with KRAS G12D mutation who received no prior systemic treatment in the advanced setting.

    Drug: TSN1611

  • Experimental
    Dose of Phase 1b/2 part of TSN1611 combination therapy-Cohort C

    Cohort C: TSN1611 combined with cetuximab and mFOLFOX6 regimen (i.e., fluorouracil, leucovorin, oxaliplatin) treating subjects with advanced CRC with KRAS G12D mutation who received no prior systemic treatment in the advanced setting.

    Drug: TSN1611

  • Experimental
    Dose of Phase 1b/2 part of TSN1611 combination therapy-Cohort D

    Cohort D: TSN1611 combined with cetuximab and FOLFIRI regimen (i.e., fluorouracil, leucovorin, irinotecan) treating participants with advanced CRC with KRAS G12D mutation who received no prior systemic treatment in the advanced setting. When the enrollment is active for both Cohort C and Cohort D simultaneously, participants could be allocated to either cohort alternatively (e.g., through randomization method), unless contradicted to either cohort.

    Drug: TSN1611

  • Experimental
    Phase 1b: Dose-finding/evaluation of TSN1611 monotherapy

    The phase 1b part will evaluate the prespecified sequential dose levels of TSN1611 in subjects with KRAS G12D mutant advanced solid tumors to determine the recommended dose of TSN1611 for further investigation.

    Drug: TSN1611

Interventions

  • DrugTSN1611

    TSN1611 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.

  • DrugTSN1611

    TSN1611 at the assigned dose level, orally, BID, combined with cetuximab, IV, every 2 weeks (Q2W), continuously in 28-day cycles

  • DrugTSN1611

    TSN1611 at the assigned dose level, orally, BID, combined with GnP regimen (gemcitabine and nab-paclitaxel), IV, on Day 1, 8 and 15, continuously in 28-day cycles

    Also known as: Paclitaxel (albumin-bound)

  • DrugTSN1611

    TSN1611 BID everyday and Patients will be administered with mFOLFOX6 on Days 1 and 2, every 2 weeks.

    Also known as: Oxaliplatin injection, fluorouracil, leucovorin

  • DrugTSN1611

    TSN1611 at the assigned dose level, orally, BID, combined with cetuximab and FOLFIRI (irinotecan, leucovorin, and fluorouracil), IV, every 2 weeks (Q2W), continuously in 28-day cycles,

    Also known as: irinotecan, leucovorin, fluorouracil

06

What researchers measure

Primary outcomes

  1. Dose limiting toxicities (DLTs) in phase 1 part

    To determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose(s) (RP2D\[s\]) of TSN1611 as monotherapy in subjects with KRAS G12D mutant advanced solid tumors.

    Time frame: 21 days

  2. Objective response rate (ORR) in phase 2 part

    To evaluate the anti-tumor activity of TSN1611 using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

    Time frame: Up to 3 years

  3. Dose limiting toxicities (DLTs) in phase 1b part of TSN1611 Combination Therapy

    Phase 1b: To determine and confirm the MTD/RP2D for TSN1611 in combination with cetuximab, in combination with cetuximab and mFOLFOX6, in combination with cetuximab and FOLFIRI, in combination with gemcitabine and albumin-bound paclitaxel in participants with selected solid tumors.

    Time frame: 28 days

  4. Objective response rate (ORR) in phase 2 part of TSN1611 Combination Therapy

    Phase 2: To evaluate the efficacy of TSN1611 in combination with cetuximab, in combination with cetuximab and mFOLFOX6, in combination with cetuximab and FOLFIRI, in combination with gemcitabine and albumin-bound paclitaxel through ORR using RECIST version 1.1.

    Time frame: Up to 3 years

Secondary outcomes

  1. Adverse events

    To assess the safety profile and tolerability of TSN1611 as monotherapy in subjects with KRAS G12D mutant advanced solid tumors.

    Time frame: Up to 3 years

  2. Area under the plasma concentration-time curve (AUC)

    To characterize the pharmacokinetic (PK) profile of TSN1611.

    Time frame: 9 weeks

  3. Maximum blood concentrations (Cmax)

    To characterize the PK profile of TSN1611.

    Time frame: 9 weeks

  4. Time to maximum blood concentration (Tmax)

    To characterize the PK profile of TSN1611.

    Time frame: 9 weeks

  5. Duration of response (DOR)

    To evaluate the anti-tumor activity of TSN1611 using RECIST version 1.1.

    Time frame: Up to 3 years

  6. Time to response (TTR)

    To evaluate the anti-tumor activity of TSN1611 using RECIST version 1.1.

    Time frame: Up to 3 years

  7. Disease control rate (DCR)

    To evaluate the anti-tumor activity of TSN1611 using RECIST version 1.1.

    Time frame: Up to 3 years

  8. Progression free survival (PFS)

    To evaluate the anti-tumor activity of TSN1611 using RECIST version 1.1.

    Time frame: Up to 3 years

  9. Overall survival

    Time frame: Up to 3 years

07

Study locations

19 of 24 sites recruiting
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
    Recruiting
    • Siqing Fu, MD,PhD · Contact
  • NEXT Oncology
    San Antonio, Texas 78229, United States
    Recruiting
    • David Sommerhalder, MD · Contact
  • NEXT Virginia
    Fairfax, Virginia 22031, United States
    Recruiting
    • Alexander Spira, MD · Contact
  • Anhui Provincial Cancer Hospital
    Hefei, Anhui, China
    Recruiting
    • Yueyin Pan · Contact
    • Yueyin Pan · Principal investigator
  • Beijing Cancer Hospital
    Beijing, Beijing Municipality, China
    Recruiting
    • Minglei Zhuo · Contact
    • Minglei Zhuo · Principal investigator
  • Peking Union Medical College Hospital
    Beijing, Beijing Municipality, China
    Not yet recruiting
    • Yuejuan Cheng, MD · Contact
    • Yuejuan Cheng · Principal investigator
  • Peking University First Hospital
    Beijing, Beijing Municipality, China
    Not yet recruiting
    • Yinmo Yang · Contact
    • Yinmo Yang · Principal investigator
  • The First Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong, China
    Recruiting
    • Chengzhi Zhou · Contact
    • Chengzhi Zhou · Principal investigator
  • Hubei Cancer Hospital
    Wuhan, Hubei, China
    Recruiting
    • Bin Yang · Contact
    • Bin Yang · Principal investigator
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei, China
    Not yet recruiting
    • Heshui Wu, MD · Contact
    • Heshui Wu · Principal investigator
  • Hunan Cancer Hospital
    Changsha, Hunan, China
    Recruiting
    • Lin Wu, MD · Contact
    • Lin Wu · Principal investigator
  • The First Affiliated Hospital of Nanchang University - Donghu District
    Nanchang, Jiang, China
    Recruiting
    • Yong Li · Contact
    • Pu Li · Contact
    • Yong Li · Principal investigator
    • Pu Li · Principal investigator
  • Linyi Cancer Hospital
    Linyi, Shandong, China
    Recruiting
    • Jianhua Shi · Contact
    • Jianhua Shi · Principal investigator
  • Ruijin Hospital-Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai Municipality, China
    Not yet recruiting
    • Boyong Shen, MD · Contact
    • Bo'yong Shen · Principal investigator
  • Shanghai Tenth People's Hospital
    Shanghai, Shanghai Municipality, China
    Recruiting
    • Xiaojun Chen · Contact
    • Xiaojun Chen · Principal investigator
  • West China Hospital, Sichuan University
    Chengdu, Sichuan, China
    Recruiting
    • Ma Ji · Contact
    • Ji Ma · Principal investigator
  • Sir Run Run Shaw Hospital - Zhejiang University School of Med
    Hangzhou, Zhejiang, China
    Recruiting
    • Haizhou Lou · Contact
    • Haizhou Lou · Principal investigator
  • The First Affiliated Hospital - Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
    Recruiting
    • Jianya Zhou · Contact
    • Jianya Zhou · Principal investigator
  • The Second Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
    Recruiting
    • Yuan Ying · Contact
    • Ying Yuan · Principal investigator
  • Taizhou Hospital of Zhejiang Province
    Taizhou, Zhejiang, China
    Recruiting
    • Dongqing Lv · Contact
    • Dongqing Lv · Principal investigator
  • Beijing Cancer Hospital, Beijing, China
    Beijing, 100142, China
    Recruiting
    • Lin Shen · Contact
    • Lin Shen, MD · Principal investigator
  • Peking Union Medical College Hospital
    Beijing, China
    Not yet recruiting
    • Taiping Zhang, MD · Contact
    • Taiping Zhang · Principal investigator
  • Shanghai Chest Hospital, Shanghai, China
    Shanghai, 200030, China
    Recruiting
    • Shun Lu · Contact
    • Shun Lu, MD · Principal investigator
  • Shanghai Zhongshan Hospital, Shanghai, China
    Shanghai, 200032, China
    Recruiting
    • Tianshu Liu · Contact
    • Tianshu Liu, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Oct 2027, 42 months after the start.

Of 197 industry-sponsored phase 1/2 interventional studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's planned 42 months is below that.

Counting every sponsor, half of 299 studies reached it within 61 months; a quarter within 40 and three quarters within 89.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Oct 2026 → Oct 2027 and completion Apr 2027 → Apr 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2024
First posted
Apr 26, 2024
StartActual
Apr 29, 2024
Primary completionEst.
Oct 30, 2027was Oct 2026
CompletionEst.
Apr 30, 2028was Apr 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added
Show 5 added (5 China)
  • Peking Union Medical College Hospital · Beijing, China
  • Peking University First Hospital · Beijing, China
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, China
  • Ruijin Hospital-Shanghai Jiao Tong University School of Medicine · Shanghai, China
  • Peking Union Medical College Hospital · Beijing, China
Nov 16, 2026
Primary completion
Oct 30, 2026→Oct 30, 2027
Nov 16, 2026
Study completion
Apr 30, 2027→Apr 30, 2028
Nov 16, 2026
Enrollment
440→570
Nov 16, 2026
Eligibility
2 criteria added
What changed in the criteria
  • AddedPhase 1b/2 Part of TSN1611 in Combination Therapies:
  • AddedSubjects with histologically or cytologically confirmed locally advanced or metastatic PDAC、CRC and NSCLC harboring KRAS G12D mutation; According to the requirements of different combined cohorts, the number of previous treatments is taken into account.
Nov 16, 2026
Interventions
Added Drug: TSN1611. Arm changed Phase 1: Dose-finding/evaluation of TSN1611 monotherapy→Phase 1a: Dose-finding/evaluation of TSN1611 monotherapy. Arms added: Dose of Phase 1b/2 part of TSN1611 combination therapy-Cohort D·Phase 1b: Dose-finding/evaluation of TSN1611 monotherapy
Nov 16, 2026
Primary outcomes
2 added
What changed in the outcomes
  • AddedDose limiting toxicities (DLTs) in phase 1b part of TSN1611 Combination TherapyTime frame: 28 days
  • AddedObjective response rate (ORR) in phase 2 part of TSN1611 Combination TherapyTime frame: Up to 3 years
Nov 16, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Linyi Cancer Hospital · Linyi, ChinaContact person changed (no phone or email listed)
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    5 sites added
    Show 5 added (5 China)
    • Peking Union Medical College Hospital · Beijing, China
    • Peking University First Hospital · Beijing, China
    • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, China
    • Ruijin Hospital-Shanghai Jiao Tong University School of Medicine · Shanghai, China
    • Peking Union Medical College Hospital · Beijing, China
    Primary completion Oct 30, 2026→Oct 30, 2027
    Study completion Apr 30, 2027→Apr 30, 2028
    Enrollment 440→570
    Eligibility 2 criteria added
    What changed in the criteria
    • AddedPhase 1b/2 Part of TSN1611 in Combination Therapies:
    • AddedSubjects with histologically or cytologically confirmed locally advanced or metastatic PDAC、CRC and NSCLC harboring KRAS G12D mutation; According to the requirements of different combined cohorts, the number of previous treatments is taken into account.
    Primary outcomes 2 added
    What changed in the outcomes
    • AddedDose limiting toxicities (DLTs) in phase 1b part of TSN1611 Combination TherapyTime frame: 28 days
    • AddedObjective response rate (ORR) in phase 2 part of TSN1611 Combination TherapyTime frame: Up to 3 years
    Interventions Added Drug: TSN1611. Arm changed Phase 1: Dose-finding/evaluation of TSN1611 monotherapy→Phase 1a: Dose-finding/evaluation of TSN1611 monotherapy. Arms added: Dose of Phase 1b/2 part of TSN1611 combination therapy-Cohort D·Phase 1b: Dose-finding/evaluation of TSN1611 monotherapy
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Linyi Cancer Hospital · Linyi, ChinaContact person changed (no phone or email listed)
    + 3 other changes: verification date, description and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06385925
Lead sponsor
Tyligand Pharmaceuticals (Suzhou) Limited
Responsible party
Sponsor
First posted
Apr 26, 2024
Start date
Apr 29, 2024
Primary completion
Oct 30, 2027 (estimated)
Completion
Apr 30, 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Tyligand Clinical Trial Info
Contact
clinical_trial@tyligand.com
+86 021-50720081
Cindy Li
study director · Tyligand Bioscience (Shanghai) Limited

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion